Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | PLAU | P00749 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | SCNN1A | P37088 | 2/20 | 0.42 |
| ▸ | SLC9A5 | Q14940 | 2/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987712 | 1.00 | NPSR1 (0.54) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL29625000 | 0.90 | SCNN1A (0.53) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL1136751 | 0.90 | SCNN1A (0.53) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL9091123 | 0.87 | NPSR1 (0.71) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL12108294 | 0.86 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL28798755 | 0.86 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL23111904 | 0.85 | NPSR1 (0.52) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL10321291 | 0.85 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL14721302 | 0.85 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1PKML3MBTL1 | |
| SCHEMBL29206055 | 0.85 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58085872-A | — | — | None | — | — | JP | disclosed |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024240242-A1 | COMPOUND CONTAINING AMIDE-SUBSTITUTED AROMATIC RING, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-117946013-B | Method for synthesizing 5, 6-dihalogen-3-aminopyrazine-2-methyl formate by one-pot method | 白银康寓信生物科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2001005769-A2 | FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION | DOW AGROSCIENCES LLC (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6156758-A | Antibacterial quinazoline compounds | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-5441955-A | Tuberculosis | PATHOGENESIS CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
| WO-1995013807-A1 | INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
| US-4604394-A | Antiarrhythmic compositions and method | MERCK & CO., INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4512991-A | 3-Acyl-2-amino-5-halo-6-(substituted)pyrazine antimicrobial compounds | MERCK & CO., INC. (US) | 1985-04-23 | — | — | US | disclosed |
| US-4507299-A | N-[2-amino-5-halo-6-(substituted)-3-pyrazinyl)-methylene]amine antimicrobial compounds | MERCK & CO., INC. (US) | 1985-03-26 | — | — | US | disclosed |
| US-4479953-A | FUNGICIDES | MERCK & CO., INC. (US) | 1984-10-30 | — | — | US | disclosed |
| JP-S5885872-A | DIHALOPYRAZINE DERIVATIVE AND AGRICULTURAL AND GARDENING FUNGICIDE | NIPPON SODA CO LTD | 1983-05-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NPSR1 4849/4885KDM4E 4105/4885ALDH1A1 4162/4885 |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | NPSR1 270/4885KDM4E 3817/4885ALDH1A1 2654/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | NPSR1 4618/4885KDM4E 3093/4885ALDH1A1 3126/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | NPSR1 4432/4885KDM4E 1206/4885ALDH1A1 1591/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | NPSR1 615/4885KDM4E 1958/4885ALDH1A1 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.